A Critical Review of Botulinum Toxin Type A in the Prophylactic Treatment of Chronic Migraine in Adults.

Background: Migraine is a severe, disabling condition, ranked by World Health Organization as the sixth highest cause of disability worldwide. It greatly affects patients' quality of life, functionality, and physical and mental health. The financial burden of migraine on the UK economy is conservatively estimated at £3.